步长制药(603858) - 2025 Q2 - 季度业绩预告

Current Period Performance Forecast The company expects significant performance growth in H1 2025, with net profit attributable to shareholders projected to rise by over 110% | Indicator | Estimated Amount (million RMB) | YoY Change (million RMB) | YoY Growth Rate | | :--- | :--- | :--- | :--- | | Net Profit Attributable to Parent Company Shareholders | 488.00 to 708.00 | +256.58 to +476.58 | +110.88% to +205.94% | | Net Profit Excluding Non-Recurring Gains/Losses | 476.00 to 702.00 | +255.02 to +481.02 | +115.40% to +217.67% | - The performance forecast applies to situations where profitability is achieved, with net profit increasing by over 50% compared to the same period last year[5] - This performance forecast is a preliminary estimate by the company's finance department and has not been audited by a certified public accountant[5][6] Prior Period Performance Overview The 2024 H1 performance serves as a benchmark, reporting net profit attributable to parent company shareholders at RMB 231.42 million | Indicator | 2024 H1 Amount | | :--- | :--- | | Total Profit | 403.97 million RMB | | Net Profit Attributable to Parent Company Shareholders | 231.42 million RMB | | Net Profit Excluding Non-Recurring Gains/Losses | 220.98 million RMB | | Earnings Per Share | 0.2110 RMB | Key Reasons for Current Period Performance Growth Performance growth is driven by expanded drug sales, reduced production costs, and significantly lower intangible asset amortization - Drug sales volume achieved year-over-year growth[9] - Production costs for key products decreased year-over-year[9] - Amortization of appraisal increments from the acquisitions of Tonghua Guhong Pharmaceutical and Jilin Tiancheng Pharmaceutical completed by the end of 2024, leading to a year-over-year reduction in current period amortization expenses[9] Risk Warning The company confirmed with its annual audit firm that no significant uncertainties affect the forecast's accuracy - The company has communicated with its annual audit firm regarding the performance forecast and found no significant uncertainties affecting its accuracy[10] Other Relevant Information The company emphasizes this is preliminary data; final figures will be in the official 2025 semi-annual report - The forecast data is preliminary, and the final financial figures will be based on the company's officially disclosed 2025 semi-annual report[11]